Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03647605
Other study ID # POIR.01.01.01-00-0636/16-00
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 13, 2018
Est. completion date January 31, 2019

Study information

Verified date January 2019
Source Tomorrow Sp. z o.o.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the pilot study is feasibility, usability and safety assessment of VR Mind intervention. In particular the subject of assessment will be:

- the length of the laboratory session utilizing virtual reality exposure (feasibility),

- the ergonomics and ease of use for both patients and system operators (usability),

- the frequency of side effect occurrence as a result of virtual reality exposure (ie. Vertigo) (safety).

The results pilot study will be used in the designing a clinical trial aimed for testing efficacy and safety of VR Mind intervention.


Description:

In this study, investigators will test the software developed by Tomorrow Sp. z o. o., named VR Mind. The software utilizes the concept of virtual reality exposure therapy to treat social anxiety disorder. The pilot investigators will be tested for the feasibility, usability and safety of the system in order to obtain information useful in further designs for the clinical trial. The research consists of four laboratory sessions. The first and the last session will be dedicated to participant assessment. During the second and third session the virtual reality scenarios (2 x 10 minutes for each session) will be presented to participants. The participants will be playing a role of someone who is giving a speech (Public speaking scenario) and someone who is speaking on a phone in public (Telephoning in public scenario).


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date January 31, 2019
Est. primary completion date January 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

1. Age: 18-50 y.o.

2. Confirmed DSM-IV-TR criteria for Social Anxiety Disorder (SAD).

3. Signing informed consent

Exclusion Criteria:

1. Occurrence of SAD symptoms inconsistent with DSM-IV-TR criteria and with psychiatric interview (SCID-I; Structured Clinical Interview)

2. Occurrence and/or recognition:

1. psychosis,

2. bipolar disorder,

3. mental retardation

3. Exclusion based on interview:

1. pregnancy,

2. drug addiction,

3. alcohol addiction,

4. participating in the experimental session while intoxicated

5. (current) neurological treatment of chronic disease of central nervous system,

6. epilepsy,

7. paroxysmal vertigo,

8. presence of suicidal thoughts , tendencies or attempts,

9. participant is taking drugs from benzodiazepine group, other sedatives, narcotic drugs

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
VR Mind
Two VR Mind sessions using virtual reality scenarios concerning social situations in which social phobics are prone to experience anxiety. The pilot study will consist of two scenarios: "Public Speaking in Lecture Hall" and "Telephoning in Public". Two sessions are planned, each containing two expositions to virtual reality environment, each lasting 10 minutes.

Locations

Country Name City State
Poland Instytut Psychiatrii i Neurologii Warszawa Mazowieckie

Sponsors (2)

Lead Sponsor Collaborator
Tomorrow Sp. z o.o. The National Centre for Research and Development

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Other Clinical Global Impression Clinical Global Impression (Guy, 1976) - is a single item, 7 point scale used by clinicians to asses the severity of illness, where 1 is labeled as "Normal, not at all ill" and 7 is labeled as "Among the most extremely ill patients". During 1st and 4th session within 2 weeks
Other Patient Global Impression Patient Global Impression - is a single item, 4 point scale used by patients to asses their impression of severity of their illness and quality of their functioning in everyday life, where 1 is labeled as "Normal" and 4 is labeled as "Severe". During 1st and 4th session within 2 weeks
Other Liebowitz Social Anxiety Scale Liebowitz Social Anxiety Scale (LSAS; Leibowitz, 1987)
The scale is composed of 24 items, depicting various social situations. For each item, participants assess their fear (from 1 - "No fear" to 4 - "Severe") and avoidance (from 1 - "Never" to 4 - "Usually").
LSAS has 3 scores, summing the results for particular items - fear (0-72), avoidance (0-72) and total score (0-144).
During 1st and 4th session within 2 weeks
Other Beck Depression Inventory During 1st and 4th session within 2 weeks
Other Subjective Units of Distress Subjective Units of Distress (SUD)
SUD is a subjective measure of perceived fear in certain situation. The scale range is from 0 ("Totally relaxed) to 100 ("Highest distress/fear/anxiety/discomfort that you have ever felt").
During 2nd and 3th session within 2 weeks
Primary Feasibility_1: Number of participants, who have completed 4 laboratory sessions within 2 weeks. Number of participants, who have completed 4 laboratory sessions within 2 weeks. At the end of 4th laboratory session within 2 weeks
Primary Feasibility_2: Number of virtual reality exposure sessions completed in predefined time. Number of virtual reality exposure sessions completed in predefined time. At the end of 2nd and 3th laboratory session within 2 weeks
Primary Usability_ 3: immersion, perceived reality and engagement 3 items with 7-point scale, where 1 is "Totally agree" and 7 "Totally disagree":
The virtual reality immersed me in all aspects (Immersion),
The virtual reality resembled true experiences (Reality),
The virtual reality was engaging (Engagement).
At the end of 2 and 3 laboratory session within 2 weeks
Primary Safety_1: occurrence and severity of simulator sickness Simulator sickness is expected adverse effect of the VR. Hence, the Simulator Sickness Questionnaire (SSQ; Kennedy, Lane, Berbaum, Lilienthal, 1993) will be administered as a primary outcome measure to evaluate safety of the VR intervention.
Total SSQ score equal to or higher than 10 will be used as a preliminary cut-off for simulator sickness (Balk et al., 2013). Individual scores will be corrected for baseline (pre-VR) symptom severity. Only items with a pre-VR - post-VR increase will contribute to a final SSQ score. All post-intervention SSQ scores >10 will be analyzed further for its association with study drop-outs and other intervention required. The adverse effect will be classified as:
mild (no intervention required, all VR sessions completed),
moderate (any intervention needed, e.g. session termination),
severe (hospitalization required),
life-threatening / death. Any unexpected adverse effects will be recorded by a physician and classified as described above.
During 2nd and 3th laboratory session within 2 weeks
See also
  Status Clinical Trial Phase
Completed NCT02256566 - Cognitive Training for Mood and Anxiety Disorders N/A
Completed NCT01570400 - Treatment of Social Phobia With Combined Cognitive Bias Modification and iCBT N/A
Recruiting NCT01388231 - Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice Phase 2/Phase 3
Completed NCT00684541 - Interpretation Modification Program for Social Phobia N/A
Completed NCT00380731 - Effect of Behavior Therapy on Responses to Social Stimuli in People With Social Phobia N/A
Completed NCT00434759 - Social Phobia Intervention Study of Mannheim N/A
Not yet recruiting NCT03241277 - Nonsurgical Periodontal Treatment in Patients With Social Phobia N/A
Completed NCT02648737 - Cognitive Behavioural Therapy for Anxiety Disorders in PD N/A
Completed NCT02294409 - Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis N/A
Terminated NCT01979263 - Attention Bias Modification Treatment for Anxious Youth N/A
Completed NCT01463137 - Attention Bias Modification Training in Social Phobia/Social Anxiety Disorder N/A
Completed NCT00774150 - Transdisciplinary Studies of CBT for Anxiety in Youth: Child Anxiety Treatment Study N/A
Completed NCT00264654 - Long-term Study Of Paroxetine in Women and Men Phase 3
Completed NCT00326430 - Residential Cognitive and Interpersonal Therapy for Social Phobia Phase 2/Phase 3
Completed NCT00000389 - Treatment for Anxiety in Children Phase 3
Completed NCT00397722 - Treatment Of Patients With Social Anxiety Disorder Phase 2
Completed NCT02678624 - Project Collabri for Treatment of Anxiety N/A
Completed NCT00564967 - A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy Phase 3
Completed NCT00403962 - A Combination Therapy In Patients With Social Anxiety Disorder Phase 2
Completed NCT00012584 - Treatment of Youth With ADHD and Anxiety N/A